Pharmacological strategies to prevent macrovascular disease in NIDDM

Diabetes

Volumn 46, Issue SUPPL. 2, 1997, Pages

  Colwell, John A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; BIGUANIDE; GEMFIBROZIL; INSULIN; METFORMIN; SULFONYLUREA;

ATHEROSCLEROSIS; CONFERENCE PAPER; DIABETIC ANGIOPATHY; DIET THERAPY; HEALTH CARE COST; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; KINESIOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; THROMBOSIS;

EID: 0030987469     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.2.s131     Document Type: Conference Paper

References (17)

1. Panzram G: Mortality and survival in type II (non-insulin-dependent diabetes mellitus). Diabetologia 30:123-131, 1987
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434-444, 1993
3. Colwell JA, Lyons TJ, Klein RL, Lopes-Virella MF: New concepts about the pathogenesis of atherosclerosis and thrombosis in diabetes mellitus. In The Diabetic Foot. Levin ME, O'Neal LW, Bowker JH, Eds. St. Louis, MO, Mosby, 1992, p. 79-114
4. Lopes-Virella MF, Jokl R, Colwell JA: Rheology and clotting factors in diabetes mellitus. In The Diabetes Annual/7. Marshal SM, Home PD, Alberti KGMM, Krall LP, Eds. Amsterdam, Elsevier, 1993, p. 83-106
5. Colwell JA, Winocour PD, Lopes-Virella MF: Platelet function and plateletplasma interactions in atherosclerosis and diabetes mellitus. In Ellenberg and Rifkn's Diabetes Mellitus: Theory and Practice. 4th ed. Rifkin H, Porte D, Eds. Amsterdam, Elsevier, 1990, p. 249-256
6. Colwell JA: Vascular thrombosis in type n diabetes mellitus. Diabetes 42:8-11, 1993
7. Colwell JA, Jokl R: Vascular thrombosis in diabetes. In Diabetes Mellitus: Theory and Practice. 5th ed. Porte D, Sherwin R, Rifkin H, Eds. Norwalk, CT, Appleton and Lange, 1996, p. 207-216
8. Kuusisto J, MyKKanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
9. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kubota M, Kajimoto Y, Kamada T: Asymptomatic hyperglycemia is associated with increased intimal plus medial thickness of the carotid artery. Diabetologia 38:585-591, 1995
10. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 (Suppl. 2):785-830, 1970
11. 1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. Diabetes 34:793-798, 1985
12. UK Prospective Diabetes Study: VIII. Study design, progress and performance. Diabetologia 34:877-890, 1991
13. Abraira C, Emanuel N, Colwell J, Henderson W, Comstock J, Levin S, Nuttal F, Sawin C, the VA Cooperative Study Group (CSDM): Glycemic control and complications in type II diabetes: design of the feasibility trial. Diabetes Care 15:1560-1571, 1992
14. Abraira C, Colwell JA, Nuttal FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuel NV, Levin SR, Henderson W, Lee HS, the VACSDM Group: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VACSDM). Diabetes Care 18:1113-1123, 1995
15. Colwell JA: The feasibility of intensive insulin management in NIDDM: implications of the VA Cooperative Study on glycemic control and complications in NIDDM. Ann Intern Med 124:131-135, 1996
16. Colwell JA: DCCT findings: applicability and implications for NIDDM. Diabetes Rev 2:277-291, 1994
17. American Diabetes Association: The pharmacological treatment of hyperglycemia in NIDDM (Consensus Statement). Diabetes Care 19 (Suppl. 1):S54-S61, 1996